Seegnal EHealth Ltd.
Seegnal is an innovative clinical decision support platform designed to enhance patient safety by providing clinicians with precise, actionable insights to prevent adverse drug reactions. The platform integrates seamlessly with Electronic Medical Records (EMR) to offer personalized medication recommendations, significantly reducing alert fatigue and improving healthcare efficiency. Seegnal's mission is to revolutionize patient care through precision medication and pharmacogenetics, empowering clinicians to deliver safer, more effective treatments. Seegnal uniquely combines precision medication with patient personal conditions to combat adverse drug reactions, offering a comprehensive solution for healthcare providers.
Industries
Nr. of Employees
small (1-50)
Patents
Method, system, and predictive computing platform for generating a reduced patient-specific data subset of drug-related adverse reaction alerts
US-10872079-B1
View Details
Method, system, and predictive computing platform for generating a reduced patient-specific data subset of drug-related adverse reaction alerts
US-10872079-B1
View DetailsProducts
Point-of-care medication decision support platform
A real-time platform that scans prescription intents and patient data to detect, prioritize, and help resolve drug-related problems while recommending safer, formulary-aware alternatives; supports pharmacogenomic inputs and continuous screening of new results.
Point-of-care medication decision support platform
A real-time platform that scans prescription intents and patient data to detect, prioritize, and help resolve drug-related problems while recommending safer, formulary-aware alternatives; supports pharmacogenomic inputs and continuous screening of new results.
Services
Technical integration with existing EHRs via a small set of APIs and plug-in/extension installation; supports cloud or on‑premises deployment and configuration to preserve clinician workflow.
Clinical pilots, silent runs, and phased rollouts in ambulatory and hospital settings including local formulary mapping, clinician change management, and deployment validation to measure clinical impact.
Integration of genotype-guided medication workflows, including pre-test recommendations, post-test interpretation, and incorporation of PGx results into EHR-based alerts and prescribing workflows.
Assessment and reporting services to estimate and monitor financial impact from medication optimization, reduced admissions, ER visits, laboratory usage, and potential malpractice exposure reductions.
Technical integration with existing EHRs via a small set of APIs and plug-in/extension installation; supports cloud or on‑premises deployment and configuration to preserve clinician workflow.
Clinical pilots, silent runs, and phased rollouts in ambulatory and hospital settings including local formulary mapping, clinician change management, and deployment validation to measure clinical impact.
Integration of genotype-guided medication workflows, including pre-test recommendations, post-test interpretation, and incorporation of PGx results into EHR-based alerts and prescribing workflows.
Assessment and reporting services to estimate and monitor financial impact from medication optimization, reduced admissions, ER visits, laboratory usage, and potential malpractice exposure reductions.
Expertise Areas
- Clinical decision support for medication safety
- Pharmacogenomics and precision medication integration
- EHR/EHR plug-in integration and interoperability
- Alert management and clinical workflow optimization
Key Technologies
- Real-time decision engine
- APIs and EHR plug-in architecture
- Microservices-based deployment
- AI/ML-driven alert prioritization
News & Updates
Seegnal's distributor in the UK, Digitals UK, has been awarded a framework contract by the UK government to sell Seegnal in the public sector.
Seegnal will present at the world's leading healthcare expo for innovation as part of the Israeli Export Institution booth.
Seegnal Poland has signed the first hospitals to pilot Seegnal and is waiting for more hospitals to join.
Leumit HMO has signed a 5-year renewal with Seegnal, upgrading to version 10.x to enhance functionality and support.
Discusses the use of Doxazosin in an 85-year-old elderly female and the associated risks.
Explores the use of Bezafibrate sustained release formulation in patients with impaired renal function.
Seegnal's distributor in the UK, Digitals UK, has been awarded a framework contract by the UK government to sell Seegnal in the public sector.
Seegnal will present at the world's leading healthcare expo for innovation as part of the Israeli Export Institution booth.
Seegnal Poland has signed the first hospitals to pilot Seegnal and is waiting for more hospitals to join.
Leumit HMO has signed a 5-year renewal with Seegnal, upgrading to version 10.x to enhance functionality and support.
Discusses the use of Doxazosin in an 85-year-old elderly female and the associated risks.
Explores the use of Bezafibrate sustained release formulation in patients with impaired renal function.